Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA Grants Prostate IDE Approval For Angiodynamics Inc's NanoKnife System


Tuesday, 18 Jun 2013 06:30am EDT 

Angiodynamics Inc announced the U.S. Food & Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to conduct a clinical study of the NanoKnife System for the ablation of focal prostate cancer. The Company is moving forward with institutional review board (IRB) submissions and anticipates commencing patient enrollment in the Company's fiscal 2014 second quarter, which ends November 30, 2013. 

Company Quote

13.985
-0.395 -2.75%
3:38pm EDT